Responses

Download PDFPDF
Novel treatment (new drug/intervention; established drug/procedure in new situation)
Successful use of tocilizumab in polymyalgic onset biopsy positive GCA with large vessel involvement
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Letter to the editor on the use of tocilizumab in GCA

    I would like to congratulate the authors on the publication of this case report. Long term treatment of giant cell arteritis (GCA) with prednisone in elderly patients is problematic with significant side effects. An effective steroid sparing agent will help clinicians in the long term management of GCA patients.

    Although this case report provides compelling evidence that TCZ is likely to be beneficial in the tr...

    Show More
    Conflict of Interest:
    None declared.